Business Description
Deltex Medical Group PLC
ISIN : GB0059337583
Description
Deltex Medical Group PLC is a British manufacturer of Fluid Management devices, which include the ODM and now ODM+ haemodynamic monitoring systems. The company has developed the gold standard for haemodynamic monitoring with oesophageal Doppler technology, which is marketed as TrueVue Doppler and often generically referred to by clinicians as ODM. The company's initial and principal technology is Doppler-based ultrasound oesophageal haemodynamic monitoring.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.37 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.58 | |||||
| Debt-to-EBITDA | -2.09 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -13.14 | |||||
| Beneish M-Score | -3.07 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -26.3 | |||||
| 3-Year EPS without NRI Growth Rate | 20.6 | |||||
| 3-Year Book Growth Rate | -26.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 100 | |||||
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 99.98 | |||||
| 6-1 Month Momentum % | 130.77 | |||||
| 12-1 Month Momentum % | -62.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | |||||
| Quick Ratio | 1.13 | |||||
| Cash Ratio | 0.75 | |||||
| Days Inventory | 441.25 | |||||
| Days Sales Outstanding | 73.51 | |||||
| Days Payable | 239.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -47.3 | |||||
| Shareholder Yield % | -0.63 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.35 | |||||
| Operating Margin % | -48.31 | |||||
| Net Margin % | -72.19 | |||||
| FCF Margin % | -88.2 | |||||
| ROE % | -50.62 | |||||
| ROA % | -21.5 | |||||
| ROIC % | -15.23 | |||||
| ROC (Joel Greenblatt) % | -325.7 | |||||
| ROCE % | -27.23 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.75 | |||||
| PB Ratio | 0.75 | |||||
| EV-to-EBIT | -3.86 | |||||
| EV-to-EBITDA | -4.42 | |||||
| EV-to-Forward-EBITDA | 15.37 | |||||
| EV-to-Revenue | 2.29 | |||||
| EV-to-Forward-Revenue | 1.65 | |||||
| EV-to-FCF | -2.59 | |||||
| Earnings Yield (Greenblatt) % | -25.91 | |||||
| FCF Yield % | -55.03 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers